How could the pace of innovation change so radically during the COVID-19 pandemic? Under non-COVID-19 circumstances, healthcare innovation can be hindered by many barriers, including lack of funding, regulatory approval processes, administrative procedures, ethics considerations, clinical trial testing, and conflicts among stakeholders, such as insurers, medical device companies, pharmaceutical corporations, hospitals, clinicians, and researchers. Priorities can change between the health concerns of patients versus business and marketing developments, which can drag the pace of healthcare improvement. The COVID-19 emergency has elicited a shortening of research and development timelines, predominantly by sidestepping administrative barriers, and focusing on health first and profit second. The innovations that are conceived, built, and utilized are developed from concept to product much faster than under typical conditions. One caveat is that these new innovations must still adhere to proper safety and efficacy protocols, and incorporate best practices for patient health and security protections. A reduction of administrative barriers should never be at the sacrifice of human well-being. All innovation initiatives need to be well thought out, examined, and tested before being rushed into practice.
It is also worth noting that increased funding from various grants and lack of executive or business priorities have helped facilitate the increase in COVID-19-related innovation. However, these are not the only reasons. COVID-19 has generated global collaboration across multiple disciplines all working together to aid communities in saving lives. This cross-functionality has been invaluable, with different educational backgrounds, lifestyles, cultures, demographics, skills, and abilities all providing unique perspectives for developing innovation. Cross-functional teams can provide greater breadth and depth of shared information, increase motivation, enhance creativity, improve task coordination, and produce less conflict among individuals (West 2002). None of this requires a need for more money or lenience of bureaucracy, but rather an optimistic outlook on cooperation. The current prosocial climate of altruism and creating open-source data-sharing hubs has never been greater. This, in turn, creates an effective and productive method of scaling healthcare innovation to other areas in need of solutions.
Although this is a hopeful perspective on healthcare innovation, there are certainly challenges involved. Innovative ideas should only be reliably implemented after numerous evidence-based research studies and demonstrated safety to patients and providers. This itself can be a difficult barrier to overcome since the gold standard method of double-blind randomized controlled trials may not be entirely feasible during a global pandemic with so many uncertainties of the disease; there is also the ethical debate of whether withholding a potential treatment outweighs the benefit of rigorous scientific experimentation. Additionally, new skills need to be learned by healthcare workers before protocols are fully implemented. Collaboration across multiple disciplines can also be burdensome if physical distancing policies prevent human contact. Ultimately, healthcare innovation is a never-ending learning process that gets refined with continuous clinical evidence. As COVID-19 runs from a sprint to a marathon, scientists and clinicians need to keep sight of the short- and long-term uptake of innovation in policy and practice.